



APPENDIX

Institutional Review Board

TO: Bradley Pearce, PhD
Principal Investigator

CC: Coleman Karlene Nursing - Main
Crawford Mackenzie Public Health
Cubells Joseph H.Genetics
Fernandez-Carriba Samuel Psychiatry - Main
Kobrynski Lisa Allergy
Oster Matthew RTP
Ousley Opal Psychiatry - Main
Patel Sheena Public Health
Sarrett Jennifer Graduate ILA

DATE: November 24, 2010

RE: **Notification of Expedited Approval**

IRB00045086

Pathophysiological mechanisms of autism risk in patients with 22q11 deletion syndrome

This is your notification that your above referenced study was reviewed and APPROVED under the Expedited review process per 45 CFR 46.110 and 21 CFR 56.110. The approval is valid from 11/23/2010 until 11/22/2011. Thereafter, continued approval is contingent upon the submission of a continuing review request that must be reviewed and approved by the IRB prior to the expiration date of this study. A waiver of informed consent and a complete HIPAA waiver are included with this approval. The inclusion of minor in the study population has been approved under 45 CFR 46.404.

Any reportable events (serious adverse events, breaches of confidentiality, protocol deviation or protocol violations) or issues resulting from this study should be reported immediately to the IRB and to the sponsoring agency (if any). Any amendments (changes to any portion of this research study including but not limited to protocol or informed consent changes) must have IRB approval before being implemented.

All correspondence and inquiries concerning this research study must include the IRB ID, the name of the Principal Investigator and the Study Title.

Sincerely,

Sarah K. Clark, CIP
Senior Research Protocol Analyst
This letter has been digitally signed